1. Seeking Convergence and Cure with New Myeloma Therapies
- Author
-
Choudhry, Priya, Galligan, Derek, and Wiita, Arun P
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Cancer ,Hematology ,Vaccine Related ,Immunization ,Rare Diseases ,Orphan Drug ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Antibodies ,Monoclonal ,Antigens ,Neoplasm ,Antigens ,Surface ,Antineoplastic Agents ,Epigenesis ,Genetic ,Humans ,Immunotherapy ,Molecular Targeted Therapy ,Multiple Myeloma ,Proteasome Inhibitors ,Small Molecule Libraries ,CAR-T ,cell surface ,epigenetics ,immunotherapy ,myeloma ,protein homeostasis ,Oncology and carcinogenesis - Abstract
For over a decade, the mainstay of multiple myeloma therapy has been small molecules that directly attack malignant plasma cell biology. However, potent immunotherapies have recently emerged, transforming the myeloma therapeutic landscape. Here we first review new promising strategies to target plasma cells through protein homeostasis and epigenetic modulators. We then discuss emerging immunotherapy strategies that are leading to dramatic results in patients. Finally, we focus on recent preclinical data suggesting that enforcing cell-surface antigen expression through small molecules may enhance immunotherapy efficacy and avoid resistance. We argue that these emerging observations point the way toward potential convergence between drug classes. With recent rapid progress we may finally be on the verge of the 'C' word: a cure for myeloma.
- Published
- 2018